Redefining the polypill: pros and cons in cardiovascular precision medicine.
CVD
LDL
NAFLD
genomics
hypertension
multi-drug
polypill
precision medicine
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2023
2023
Historique:
received:
27
07
2023
accepted:
08
09
2023
medline:
6
10
2023
pubmed:
6
10
2023
entrez:
6
10
2023
Statut:
epublish
Résumé
Polypill is a multi-drug formulation in a single pill intended to simplify the drug regimen and reduce medication-induced adverse effects. The most common multidrug combinations in a polypill are used to treat cardiovascular diseases and are targeted against key modifiable risk factors such as hypertension and hyperlipidemia. These contain blood-pressure lowering agents, statins, and anti-platelet agents usually in a fixed dose. Polypills can be an affordable therapeutic intervention for treating high-risk patients, as these are proven to increase patients' adherence to medication and improve clinical outcomes. Over the previous years, randomized clinical trials of several polypills have yielded contradictory findings, raising skepticism regarding their widespread use in primary disease prevention. Here, we have reviewed the concept of polypills, the evidence-based strengths, the limitations of this polypharmacy intervention strategy, and discussed future directions for their use in the primary and secondary preventive management of cardiovascular diseases and associated risk factors.
Identifiants
pubmed: 37799963
doi: 10.3389/fphar.2023.1268119
pii: 1268119
pmc: PMC10549989
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1268119Informations de copyright
Copyright © 2023 Birla, Angural, Madathumchalil, Shende, Shastry, Mahadevappa, Shambhu, Vishwanath and Prashant.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Ann Intern Med. 2005 Oct 18;143(8):593-9
pubmed: 16230726
BMC Cardiovasc Disord. 2022 Dec 22;22(1):560
pubmed: 36550424
Circ J. 2014;78(2):507-33
pubmed: 24369273
J Am Coll Cardiol. 2014 Nov 18-25;64(20):2071-82
pubmed: 25193393
Curr Probl Cardiol. 2023 Aug;48(8):101233
pubmed: 35490770
Curr Probl Cardiol. 2023 Aug;48(8):101735
pubmed: 37044270
BMC Pharmacol Toxicol. 2017 Feb 7;18(1):10
pubmed: 28166827
J R Soc Med. 2009 Dec;102(12):509-12
pubmed: 19966125
Lancet. 2002 Jul 6;360(9326):2-3
pubmed: 12114031
Hypertension. 2018 Jun;71(6):1269-1324
pubmed: 29133354
Curr Hypertens Rep. 2016 Apr;18(5):40
pubmed: 27083928
JAMA Neurol. 2023 Mar 1;80(3):251-259
pubmed: 36716007
N Engl J Med. 2022 Sep 15;387(11):967-977
pubmed: 36018037
Eur Heart J. 2018 Jan 7;39(2):119-177
pubmed: 28886621
Stroke. 2022 Aug;53(8):2695-2701
pubmed: 35726621
Circulation. 2010 Nov 16;122(20):2078-88
pubmed: 21098469
Am J Med. 2009 Mar;122(3):290-300
pubmed: 19272490
Int J Environ Res Public Health. 2019 Aug 26;16(17):
pubmed: 31455011
Health Aff (Millwood). 2011 Jan;30(1):91-9
pubmed: 21209444
N Engl J Med. 2016 May 26;374(21):2032-43
pubmed: 27039945
J Clin Hypertens (Greenwich). 2021 Mar;23(3):545-555
pubmed: 33086429
BMJ Open. 2015 May 09;5(5):e007111
pubmed: 25991449
BMJ. 2003 Jun 28;326(7404):1427
pubmed: 12829555
Pol Arch Intern Med. 2023 Mar 29;133(3):
pubmed: 36916535
Pediatrics. 2009 Jul;124(1):324-32
pubmed: 19564316
Nat Med. 2022 Feb;28(2):226-229
pubmed: 35102336
N Engl J Med. 2016 May 26;374(21):2021-31
pubmed: 27040132
Int J Cardiol. 2018 Jul 1;262:71-78
pubmed: 29622506
Prog Cardiovasc Dis. 2022 Jul-Aug;73:48-55
pubmed: 35114251
Glob Heart. 2020 Aug 19;15(1):57
pubmed: 32923350
J Clin Hypertens (Greenwich). 2011 Dec;13(12):898-909
pubmed: 22142349
Int J Cardiol. 2018 Feb 1;252:181-186
pubmed: 29180263
Eur Heart J. 2022 Jun 1;43(21):2023-2033
pubmed: 35048107
Hypertension. 2010 Feb;55(2):399-407
pubmed: 20026768
J Am Coll Cardiol. 2012 Dec 25;60(25 Suppl):S1-49
pubmed: 23257320
Int J Cardiol. 2022 Aug 1;360:91-98
pubmed: 35641323
Lancet. 2007 Dec 15;370(9604):2054-62
pubmed: 18063025
BMJ. 2003 Jun 28;326(7404):1423
pubmed: 12829554
Ann Glob Health. 2014 Jan-Feb;80(1):24-34
pubmed: 24751562
Trends Cardiovasc Med. 2023 Apr;33(3):182-189
pubmed: 34973412
Glob Heart. 2015 Jun;10(2):99-110
pubmed: 26213297
N Engl J Med. 2016 May 26;374(21):2009-20
pubmed: 27041480
Lancet. 2019 Aug 24;394(10199):672-683
pubmed: 31448738
Pediatrics. 2016 Dec;138(6):
pubmed: 27940711
BMJ. 2003 Jun 28;326(7404):1419
pubmed: 12829553
Int J Mol Sci. 2021 Apr 17;22(8):
pubmed: 33920733
Blood Press. 2014 Feb;23(1):3-16
pubmed: 24359485
N Engl J Med. 2019 Sep 19;381(12):1114-1123
pubmed: 31532959
Cardiol Ther. 2020 Jun;9(1):19-34
pubmed: 31933276
J Epidemiol Community Health. 2003 Feb;57(2):134-40
pubmed: 12540690
Curr Probl Cardiol. 2022 Jun;47(6):100872
pubmed: 34016484
Am J Cardiovasc Drugs. 2010;10(2):95-103
pubmed: 20334446
Eur Heart J. 2018 Sep 1;39(33):3021-3104
pubmed: 30165516
Int J Cardiol. 2022 Aug 15;361:116-123
pubmed: 35569611
Sci Rep. 2021 Mar 25;11(1):6880
pubmed: 33767231
Clinicoecon Outcomes Res. 2023 Jul 19;15:559-571
pubmed: 37489131
Circulation. 2020 Jun 9;141(23):e884-e903
pubmed: 32362133
N Engl J Med. 2021 Jan 21;384(3):216-228
pubmed: 33186492
J Health Econ Outcomes Res. 2022 Nov 22;9(2):134-146
pubmed: 36475278
J Clin Hypertens (Greenwich). 2014 Jan;16(1):14-26
pubmed: 24341872
Circulation. 2019 Nov 26;140(22):1776-1778
pubmed: 31765254